PURPOSE: Several formulations have been proposed to improve the systemic delivery of novel cancer therapeutic compounds, including cyclodextrin derivatives. We aimed to synthesize and characterize of CDF-β-cyclodextrin inclusion complex (1:2) (CDFCD). METHODS: The compound was characterized by Fourier transform infrared, differential scanning calorimetry, powder X-ray diffraction studies, H1 & C13 NMR studies and scanning electron microscopic analysis. Its activity was tested against multiple cancer cell lines, and in vivo bioavailability was checked. RESULTS: CDF-β-cyclodextrin was found to lower IC(50) value by half when tested against multiple cancer cell lines. It preferentially accumulated in the pancreas, where levels of CDF-β-cyclodextrin in mice were 10 times higher than in serum, following intravenous administration of an aqueous CDF-β-cyclodextrin preparation. CONCLUSIONS: Novel curcumin analog CDF preferentially accumulates in the pancreas, leading to its potent anticancer activity against pancreatic cancer cells. Synthesis of such CDF-β-cyclodextrin self-assembly is an effective strategy to enhance its bioavailability and tissue distribution, warranting further evaluation for CDF delivery in clinical settings for treatment of human malignancies.
PURPOSE: Several formulations have been proposed to improve the systemic delivery of novel cancer therapeutic compounds, including cyclodextrin derivatives. We aimed to synthesize and characterize of CDF-β-cyclodextrin inclusion complex (1:2) (CDFCD). METHODS: The compound was characterized by Fourier transform infrared, differential scanning calorimetry, powder X-ray diffraction studies, H1 & C13 NMR studies and scanning electron microscopic analysis. Its activity was tested against multiple cancer cell lines, and in vivo bioavailability was checked. RESULTS:CDF-β-cyclodextrin was found to lower IC(50) value by half when tested against multiple cancer cell lines. It preferentially accumulated in the pancreas, where levels of CDF-β-cyclodextrin in mice were 10 times higher than in serum, following intravenous administration of an aqueous CDF-β-cyclodextrin preparation. CONCLUSIONS: Novel curcumin analog CDF preferentially accumulates in the pancreas, leading to its potent anticancer activity against pancreatic cancer cells. Synthesis of such CDF-β-cyclodextrin self-assembly is an effective strategy to enhance its bioavailability and tissue distribution, warranting further evaluation for CDF delivery in clinical settings for treatment of humanmalignancies.
Authors: Shadan Ali; Aamir Ahmad; Sanjeev Banerjee; Subhash Padhye; Kristin Dominiak; Jacqueline M Schaffert; Zhiwei Wang; Philip A Philip; Fazlul H Sarkar Journal: Cancer Res Date: 2010-04-13 Impact factor: 12.701
Authors: Ana Cláudia Santos; Diana Costa; Laura Ferreira; Catarina Guerra; Miguel Pereira-Silva; Irina Pereira; Diana Peixoto; Nuno R Ferreira; Francisco Veiga Journal: Drug Deliv Transl Res Date: 2021-02 Impact factor: 4.617
Authors: Irfana Muqbil; Ginny W Bao; Rkya El-Kharraj; Minjel Shah; Ramzi M Mohammad; Fazlul H Sarkar; Asfar S Azmi Journal: J Stem Cell Res Ther Date: 2012-12-16
Authors: Murali M Yallapu; Mara C Ebeling; Sheema Khan; Vasudha Sundram; Neeraj Chauhan; Brij K Gupta; Susan E Puumala; Meena Jaggi; Subhash C Chauhan Journal: Mol Cancer Ther Date: 2013-05-23 Impact factor: 6.261